Checkpoint Therapeutics CKPT 深 沪
等待开盘 04-07 09:30:00 美东时间
4.26
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 4.26
- 总市值 3.71亿
- 52周最高 4.50
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.80
- 委 比 0.00%
- 总股本 8702.00万
- 历史最高 105.00
- 量 比 0
- 振 幅 0.00%
- 历史最低 1.30
- 每 手 1
- 风险率 0.08%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Fortress Biotech And Cyprium Therapeutics Announce The Closing Of The Sale Of Cyprium's Rare Pediatric Disease Priority Review Voucher For Gross Proceeds Of $205M
Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing of the sale of Cyprium's Rare Pediatric Disease Priority Review
03-31 04:17
Fortress Biotech’s Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
Fortress Biotech and its subsidiary Cyprium Therapeutics announce the sale of Cyprium’s Rare Pediatric Disease Priority Review Voucher for $205 million. Fortress, as the majority shareholder, expects to receive over $100 million, enhancing its financial flexibility. The transaction follows three FDA approvals in the past 15 months and the sale of Checkpoint Therapeutics. Cyprium will continue to earn royalties and milestones from ZYCUBO sales and...
03-30 20:05
Fortress Biotech’s Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
Cyprium Therapeutics已将其罕见儿科疾病优先审评券以2.05亿美元出售，并将部分收益支付给NIH。Sentynl接手ZYCUBO，Cyprium仍享有销售分成和里程碑付款。CEO指出，此交易助力Fortress今年盈利，同时公司在推进基因疗法开发。
02-23 13:30
Fortress Biotech Announces Closing of Sale of Subsidiary Checkpoint Therapeutics
Fortress Biotech's subsidiary, Checkpoint Therapeutics, has been acquired by Sun Pharma for $4.10 per share in cash, plus a contingent value right (CVR) up to $0.70 per share. Fortress will receive ~$28 million immediately, a 2.5% royalty on UNLOXCYT™ sales, and up to $4.8 million via CVR if certain conditions are met. UNLOXCYT™, the first FDA-approved PD-L1 blocker for advanced cutaneous squamous cell carcinoma, will be commercialized globally v...
2025-05-30 14:47
Checkpoint Therapeutics Reports Q1 2025 Financials and Updates
Checkpoint Therapeutics ( ($CKPT) ) has released its Q1 earnings. Here is a bre...
2025-05-24 11:50
Checkpoint Therapeutics Q1 EPS $(0.19) Misses $(0.17) Estimate
Checkpoint Therapeutics (NASDAQ:CKPT) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 42.42 percent increase over losses of $(0.33) per
2025-05-14 04:42
Checkpoint Therapeutics Inc <CKPT.OQ> expected to post a loss of 17 cents a share - Earnings Preview
Checkpoint Therapeutics Inc CKPT.OQ CKPT.O is expected to show no change in quarterly revenue when it reports results on May 12 (estimated) for the period ending March 31 2025 LSEG's mean analyst est...
2025-05-09 22:18
美股大行评级 | 潜在涨幅778.38%！HC Wainwright & Co.上调BioLine Rx目标价至26美元，维持"买入"评级
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1113752959213998081.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持BioLine Rx(BLRX)"买入"评级，目标价从9美元升至26美元</p> <p>• 德银：上调固特异轮胎橡胶(GT)评级至"买入"，目标价13美元</p> <p
2025-04-01 09:48
Checkpoint Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary
Checkpoint Therapeutics Inc CKPT.OQ reported a quarterly adjusted loss of 69 cents per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS ...
2025-03-28 20:55
Checkpoint Therapeutics GAAP EPS of -$1.42
Checkpoint Therapeutics press release (NASDAQ:CKPT): FY GAAP EPS of -$1.42. As of December 31, 2024, Checkpoint’s cash and cash equivalents totaled $6.6 million, compared to $4.9 million at December 3...
2025-03-28 20:32
